Merus, which is developing bispecific antibody treatments for solid tumors, filed on Monday with the SEC to raise up to $60 million in an initial public offering.
The Utrecht, Netherlands-based company, which was founded in 2003 and booked $2 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol MRUS. Merus filed confidentially on September 8, 2015. Citi and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
